Marketing-authorisation holder
3 medicines in 1 country, as authorisation holder.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Every medicine in the registers under its name, current ones first.
3 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| TEVIMBRA10 mg/mL · Injectable | Islelizumab | United States | Marketed | 2025 |
| TEVIMBRA100mg/10ml · Injection | Tislelizumab | United States | Marketed | 2024 |
| TEVIMBRA100mg/10ml(10mg/ml) · Injectable | Tislelizumab | United States | Marketed | 2024 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 3 | 3 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Report an error or request removalCorrections from the company itself are welcome.
Keep Beigene’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a call
